Frontiers in Oncology (Jun 2021)
Anti-Tumor Effects of BDH1 in Acute Myeloid Leukemia
- Fei Han,
- Fei Han,
- Fei Han,
- Huanhuan Zhao,
- Huanhuan Zhao,
- Huanhuan Zhao,
- Jun Lu,
- Jun Lu,
- Jun Lu,
- Weina Yun,
- Weina Yun,
- Weina Yun,
- Lingling Yang,
- Lingling Yang,
- Lingling Yang,
- Yude Lou,
- Yude Lou,
- Yude Lou,
- Dan Su,
- Dan Su,
- Dan Su,
- Xin Chen,
- Xin Chen,
- Xin Chen,
- Shixuan Zhang,
- Shixuan Zhang,
- Shixuan Zhang,
- Hanwei Jin,
- Hanwei Jin,
- Hanwei Jin,
- Xiang Li,
- Xiang Li,
- Xiang Li,
- Jie Sun,
- Jie Sun,
- He Huang,
- He Huang,
- He Huang,
- Qishan Wang,
- Xi Jiang,
- Xi Jiang,
- Xi Jiang
Affiliations
- Fei Han
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Fei Han
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Fei Han
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Huanhuan Zhao
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Huanhuan Zhao
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Huanhuan Zhao
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Jun Lu
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Jun Lu
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Jun Lu
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Weina Yun
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Weina Yun
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Weina Yun
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Lingling Yang
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Lingling Yang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Lingling Yang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Yude Lou
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Yude Lou
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Yude Lou
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Dan Su
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Dan Su
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Dan Su
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Xin Chen
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xin Chen
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Xin Chen
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Shixuan Zhang
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Shixuan Zhang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Shixuan Zhang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Hanwei Jin
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Hanwei Jin
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Hanwei Jin
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Xiang Li
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xiang Li
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Xiang Li
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- Jie Sun
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Jie Sun
- Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- He Huang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- He Huang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- He Huang
- Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Qishan Wang
- College of Animal Sciences, Zhejiang University, Hangzhou, China
- Xi Jiang
- Department of Pharmacology and Bone Marrow Transplantation Center of the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
- Xi Jiang
- Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, China
- Xi Jiang
- Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
- DOI
- https://doi.org/10.3389/fonc.2021.694594
- Journal volume & issue
-
Vol. 11
Abstract
Dysregulation of ketone metabolism has been reported in various types of cancer. In order to find out its role in acute myeloid leukemia (AML) pathogenesis, we first analyzed the expression levels of 10 key genes involved in ketone metabolism in AML blasts and CD34+ hematopoietic stem cells (HSCs) from healthy donors. We found that the expression level of BDH1 was significantly lower in AML than in normal HSCs. The downregulation of BDH1 gene expression in AML cell lines as compared with normal HSCs was further confirmed with real-time RT-PCR. Analysis of TCGA and other database revealed that the downregulation of BDH1 was associated with worse prognosis in AML patients. In addition, we showed that overexpression of BDH1 inhibited the viability and proliferation of AML cells. In contrast, BDH1 knock-down promoted AML cell growth. Collectively, our results suggest the previously unappreciated anti-tumor role of BDH1 in AML, and low BDH1 expression predicts poor survival.
Keywords
